Floatz logo

Carfilzomib

Relapsed or Refractory

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Relapsed or Refractory cohort.

Asset / SponsorPhaseRating
Chiauranib
Chipscreen Biosciences, Ltd.
Phase 3B
cc-5013
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
DEXAMETHASONE
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Romidepsin
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
MRDDormant
BB
Indicative ·
64 / 100
View asset →
Stage III Adult Diffuse Large Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →